Kurs
0,00%
Kurs
0,00%
Open
48,50
High
48,50
Low
48,00
Close
48,50
Kursutveckling under dagen för detta pressmeddelande
(NOK).
Likviditet
0,26 MNOK
Likviditet
0,26 MNOK
Rel. mcap
0,03%
Antal aktier
5 267
Likviditet under dagen för detta pressmeddelande
Kalender
| Est. tid* | ||
| 2025-10-23 | 08:00 | Kvartalsrapport 2025-Q3 |
| 2025-07-10 | 08:00 | Kvartalsrapport 2025-Q2 |
| 2025-05-07 | - | X-dag ordinarie utdelning GENT 0.40 NOK |
| 2025-05-07 | - | Kvartalsrapport 2025-Q1 |
| 2025-05-06 | - | Årsstämma |
| 2025-02-12 | - | Bokslutskommuniké 2024 |
| 2024-10-31 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-29 | - | Kvartalsrapport 2024-Q2 |
| 2024-04-30 | - | X-dag ordinarie utdelning GENT 0.00 NOK |
| 2024-04-30 | - | Kvartalsrapport 2024-Q1 |
| 2024-04-29 | - | Årsstämma |
| 2024-02-09 | - | Bokslutskommuniké 2023 |
| 2023-10-26 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-24 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-05 | - | X-dag ordinarie utdelning GENT 0.00 NOK |
| 2023-05-05 | - | Kvartalsrapport 2023-Q1 |
| 2023-05-04 | - | Årsstämma |
| 2023-02-16 | - | Bokslutskommuniké 2022 |
| 2022-10-27 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-25 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-19 | - | X-dag ordinarie utdelning GENT 0.00 NOK |
| 2022-05-18 | - | Årsstämma |
| 2022-04-28 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-17 | - | Bokslutskommuniké 2021 |
| 2021-10-21 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-25 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-05 | - | X-dag ordinarie utdelning GENT 0.00 NOK |
| 2021-05-04 | - | Årsstämma |
| 2021-04-16 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-11 | - | Bokslutskommuniké 2020 |
| 2020-10-29 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-21 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-15 | - | X-dag ordinarie utdelning GENT 0.00 NOK |
| 2020-05-14 | - | Årsstämma |
| 2020-04-24 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-14 | - | Bokslutskommuniké 2019 |
| 2019-11-21 | - | Extra Bolagsstämma 2019 |
| 2019-05-10 | - | X-dag ordinarie utdelning GENT 0.00 NOK |
| 2018-07-13 | - | Extra Bolagsstämma 2018 |
| 2018-06-13 | - | X-dag ordinarie utdelning GENT 0.00 NOK |
| 2018-02-27 | - | Bokslutskommuniké 2017 |
| 2017-06-06 | - | Årsstämma |
Beskrivning
| Land | Norge |
|---|---|
| Lista | Oslo Bors |
| Sektor | Hälsovård |
| Industri | Bioteknik |
2019-06-28 08:00:00
Moss, 28.06.2019 Gentian Diagnostics AS is pleased to announce that BÜHLMANN has received 510(k) clearance (K190784) from the FDA for the BÜHLMANN fCAL® turbo. BÜHLMANN is Gentian’s exclusive commercial partner for the fecal calprotectin products worldwide. The potential US fecal calprotectin market is of an estimated size of USD ~30 million, while the current market is of an estimated size of USD ~5 million. Hilja Ibert, CEO Gentian Diagnostics AS comments “While the fecal calprotectin market size in the US is still quite small, fecal calprotectin is part of a high annual growth market, as observed in Europe. The already FDA cleared BÜHLMANN fCAL® ELISA has paved the way for BÜHLMANN fCAL® turbo which will allow for high throughput analysis of fecal calprotectin in applicable core laboratories and screening programmes.” For further information, please contact: Hilja Ibert CEO, Gentian Diagnostics AS E-mail: hilja.ibert@gentian.no Cell Phone: +47 919 05 242 Njaal Kind CFO, Gentian Diagnostics AS E-mail: njaal.kind@gentian.no Cell Phone: +47 919 06 525